Demographics of the study population (n = 2709)
| Characteristic . | Total . | A,B matched* . | Minor MM† . | Major MM† . | P‡ . |
|---|---|---|---|---|---|
| Disease, no. (%) | .42 | ||||
| Chronic myelogenous leukemia | 1071 (40) | 933 (40) | 51 (38) | 87 (33) | |
| Chronic phase | 824 (30) | 723 (31) | 33 (24) | 68 (26) | |
| Accelerated phase | 187 (7) | 160 (7) | 12 (9) | 15 (6) | |
| Blast phase | 60 (2) | 50 (2) | 6 (4) | 4 (2) | |
| Acute myelogenous leukemia | 755 (28) | 640 (28) | 40 (29) | 75 (29) | |
| First CR | 170 (6) | 149 (6) | 8 (6) | 13 (5) | |
| Second CR | 214 (8) | 182 (8) | 17 (13) | 15 (6) | |
| Third or higher CR | 19 (1) | 17 (1) | 0 (0) | 2 (1) | |
| Relapse§ | 352 (13) | 292 (13) | 15 (11) | 45 (17) | |
| Acute lymphoblastic leukemia | 637 (24) | 523 (23) | 39 (29) | 75 (29) | |
| First CR | 161 (6) | 136 (6) | 13 (10) | 12 (5) | |
| Second CR | 224 (8) | 181 (8) | 9 (7) | 34 (13) | |
| Third or higher CR | 81 (3) | 62 (3) | 8 (6) | 11 (4) | |
| Relapse§ | 171 (6) | 144 (6) | 9 (7) | 18 (7) | |
| Myelodysplastic disorders | 246 (9) | 217 (9) | 6 (4) | 23 (9) | |
| Refractory anemia | 92 (3) | 82 (4) | 2 (1) | 8 (3) | |
| RAEB | 82 (3) | 75 (3) | 3 (2) | 4 (2) | |
| RAEBIT | 72 (3) | 60 (3) | 1 (1) | 11 (4) | |
| T-cell depletion, no. (%) | 528 (19) | 416 (18) | 36 (26) | 76 (29) | .56 |
| HLA-C match, no. (%) | |||||
| C allele match | 2011 (74) | 1835 (79) | 56 (41) | 120 (46) | .34 |
| C allele mismatch | 698 (26) | 478 (21) | 80 (59) | 140 (54) | |
| Cell sources, no. (%) | .79 | ||||
| Bone marrow | 2516 (93) | 2136 (93) | 131 (96) | 249 (96) | |
| Peripheral blood | 193 (7) | 177 (8) | 5 (4) | 11 (4) | |
| Karnofsky/Lansky score at transplantation,∥ no. (%) | .97 | ||||
| 90 to 100 | 1966 (73) | 1668 (72) | 101 (74) | 197 (76) | |
| 10 to 90 | 667 (25) | 575 (25) | 31 (23) | 61 (23) | |
| Unknown | 76 (3) | 70 (3) | 4 (3) | 2 (1) | |
| Recipient sex, no. (%) | .99 | ||||
| Female | 1180 (44) | 1008 (44) | 59 (43) | 113 (43) | |
| Male | 1529 (56) | 1305 (56) | 77 (57) | 147 (57) | |
| Donor/recipient CMV status at transplantation, no. (%) | .96 | ||||
| Negative/negative | 974 (36) | 845 (37) | 44 (32) | 85 (33) | |
| Negative/positive | 756 (28) | 647 (28) | 39 (29) | 70 (27) | |
| Positive/negative | 440 (16) | 370 (16) | 23 (17) | 47 (18) | |
| Positive/positive | 460 (17) | 386 (17) | 24 (18) | 50 (19) | |
| Unknown | 79 (3) | 65 (3) | 6 (4) | 8 (3) | |
| Racial or ethnic background, no. (%) | .46 | ||||
| White | 2479 (92) | 2151 (93) | 110 (81) | 218 (84) | |
| Other | 230 (8) | 162 (7) | 26 (19) | 42 (16) | |
| Year of transplantation, no. (%) | .51 | ||||
| 1988 to 1992 | 384 (14) | 303 (13) | 31 (23) | 50 (19) | |
| 1993 to 1995 | 547 (20) | 459 (20) | 33 (24) | 55 (21) | |
| 1996 to 1999 | 957 (35) | 837 (36) | 41 (30) | 79 (30) | |
| 2000 to 2003 | 821 (30) | 714 (31) | 31 (23) | 76 (29) | |
| Median recipient age, y (range) | 32 (< 1-65) | 32 (< 1-65) | 28 (< 1-55) | 27 (< 1-55) | .38 |
| Median donor age, y (range) | 36 (18-60) | 36 (18-60) | 35 (18-57) | 37 (19-59) | .16 |
| Median disease duration, mo (range)∥ | 20 (< 1-309) | 19 (< 1-309) | 24 (< 1-148) | 24 (1-161) | .47 |
| Characteristic . | Total . | A,B matched* . | Minor MM† . | Major MM† . | P‡ . |
|---|---|---|---|---|---|
| Disease, no. (%) | .42 | ||||
| Chronic myelogenous leukemia | 1071 (40) | 933 (40) | 51 (38) | 87 (33) | |
| Chronic phase | 824 (30) | 723 (31) | 33 (24) | 68 (26) | |
| Accelerated phase | 187 (7) | 160 (7) | 12 (9) | 15 (6) | |
| Blast phase | 60 (2) | 50 (2) | 6 (4) | 4 (2) | |
| Acute myelogenous leukemia | 755 (28) | 640 (28) | 40 (29) | 75 (29) | |
| First CR | 170 (6) | 149 (6) | 8 (6) | 13 (5) | |
| Second CR | 214 (8) | 182 (8) | 17 (13) | 15 (6) | |
| Third or higher CR | 19 (1) | 17 (1) | 0 (0) | 2 (1) | |
| Relapse§ | 352 (13) | 292 (13) | 15 (11) | 45 (17) | |
| Acute lymphoblastic leukemia | 637 (24) | 523 (23) | 39 (29) | 75 (29) | |
| First CR | 161 (6) | 136 (6) | 13 (10) | 12 (5) | |
| Second CR | 224 (8) | 181 (8) | 9 (7) | 34 (13) | |
| Third or higher CR | 81 (3) | 62 (3) | 8 (6) | 11 (4) | |
| Relapse§ | 171 (6) | 144 (6) | 9 (7) | 18 (7) | |
| Myelodysplastic disorders | 246 (9) | 217 (9) | 6 (4) | 23 (9) | |
| Refractory anemia | 92 (3) | 82 (4) | 2 (1) | 8 (3) | |
| RAEB | 82 (3) | 75 (3) | 3 (2) | 4 (2) | |
| RAEBIT | 72 (3) | 60 (3) | 1 (1) | 11 (4) | |
| T-cell depletion, no. (%) | 528 (19) | 416 (18) | 36 (26) | 76 (29) | .56 |
| HLA-C match, no. (%) | |||||
| C allele match | 2011 (74) | 1835 (79) | 56 (41) | 120 (46) | .34 |
| C allele mismatch | 698 (26) | 478 (21) | 80 (59) | 140 (54) | |
| Cell sources, no. (%) | .79 | ||||
| Bone marrow | 2516 (93) | 2136 (93) | 131 (96) | 249 (96) | |
| Peripheral blood | 193 (7) | 177 (8) | 5 (4) | 11 (4) | |
| Karnofsky/Lansky score at transplantation,∥ no. (%) | .97 | ||||
| 90 to 100 | 1966 (73) | 1668 (72) | 101 (74) | 197 (76) | |
| 10 to 90 | 667 (25) | 575 (25) | 31 (23) | 61 (23) | |
| Unknown | 76 (3) | 70 (3) | 4 (3) | 2 (1) | |
| Recipient sex, no. (%) | .99 | ||||
| Female | 1180 (44) | 1008 (44) | 59 (43) | 113 (43) | |
| Male | 1529 (56) | 1305 (56) | 77 (57) | 147 (57) | |
| Donor/recipient CMV status at transplantation, no. (%) | .96 | ||||
| Negative/negative | 974 (36) | 845 (37) | 44 (32) | 85 (33) | |
| Negative/positive | 756 (28) | 647 (28) | 39 (29) | 70 (27) | |
| Positive/negative | 440 (16) | 370 (16) | 23 (17) | 47 (18) | |
| Positive/positive | 460 (17) | 386 (17) | 24 (18) | 50 (19) | |
| Unknown | 79 (3) | 65 (3) | 6 (4) | 8 (3) | |
| Racial or ethnic background, no. (%) | .46 | ||||
| White | 2479 (92) | 2151 (93) | 110 (81) | 218 (84) | |
| Other | 230 (8) | 162 (7) | 26 (19) | 42 (16) | |
| Year of transplantation, no. (%) | .51 | ||||
| 1988 to 1992 | 384 (14) | 303 (13) | 31 (23) | 50 (19) | |
| 1993 to 1995 | 547 (20) | 459 (20) | 33 (24) | 55 (21) | |
| 1996 to 1999 | 957 (35) | 837 (36) | 41 (30) | 79 (30) | |
| 2000 to 2003 | 821 (30) | 714 (31) | 31 (23) | 76 (29) | |
| Median recipient age, y (range) | 32 (< 1-65) | 32 (< 1-65) | 28 (< 1-55) | 27 (< 1-55) | .38 |
| Median donor age, y (range) | 36 (18-60) | 36 (18-60) | 35 (18-57) | 37 (19-59) | .16 |
| Median disease duration, mo (range)∥ | 20 (< 1-309) | 19 (< 1-309) | 24 (< 1-148) | 24 (1-161) | .47 |
CR indicates complete remission; RAEB, refractory anemia with excess blasts; RAEBIT, refractory anemia with excess blasts in transformation; and CMV, cytomegalovirus.
All pairs are matched for HLA-A, HLA-B, and HLA-DRB1 alleles.
Based on Rodey CREG scheme2,3 ; results were similar for Thompson et al22 and Takemoto6 CREG schemes. These transplants are mismatched for a single allele at HLA-A or HLA-B but matched for all other alleles at HLA-A, HLA-B, and HLA-DRB1.
P values comparing minor versus major mismatches using the chi-square statistic for discrete variables and the Wilcoxon rank-sum test for continuous variables.
Includes primary induction failures.
Diagnosis date missing in 11 cases.